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Abstract
Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are cardiac hormones that 
regulate blood pressure and volume, and exert their biological actions via the natriuretic peptide 
receptor-A gene (Npr1). Mice lacking Npr1 (Npr–/–) have marked cardiac hypertrophy and fibrosis 
disproportionate to their increased blood pressure. This study examined the relationships between 
ANP and BNP gene expression, immunoreactivity and fibrosis in cardiac tissue, circulating ANP 
levels, and ANP and BNP mRNA during embryogenesis in Npr1–/– mice. Disruption of the Npr1 
signaling pathway resulted in augmented ANP and BNP gene and ANP protein expression in the 
cardiac ventricles, most pronounced for ANP mRNA in females [414 ± 57 in Npr1–/– ng/mg and 
124 ± 25 ng/mg in wild-type (WT) by Taqman assay, P < 0.001]. This increased expression was 
highly correlated to the degree of cardiac hypertrophy and was localized to the left ventricle (LV) 
inner free wall and to areas of ventricular fibrosis. In contrast, plasma ANP was significantly 
greater than WT in male but not female Npr1–/– mice. Increased ANP and BNP gene expression 
was observed in Npr1–/– embryos from 16 days of gestation. Our study suggests that cardiac 
ventricular expression of ANP and BNP is more closely associated with local hypertrophy and 
fibrosis than either systemic blood pressure or circulating ANP levels.
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NATRIURETIC PEPTIDES are a family of hormones that regulate blood pressure and body fluid 
homeostasis through their combined actions on vasculature, kidneys, and adrenal glands. 
Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are predominantly 
produced by cardiac atria and ventricles, respectively, in response to increased cardiac 
stretch. ANP and BNP exert their biological actions by binding to the natriuretic peptide 
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receptor-A (NPR-A), resulting in the generation of the second messenger cGMP. These two 
natriuretic peptides have pronounced hypotensive, diuretic, and natriuretic effects (8).
Plasma levels of ANP and BNP are markedly elevated in heart failure (17) and after 
myocardial infarction (MI) (9) and are powerful predictors of ventricular dysfunction and 
mortality (14). Moreover, within heart tissue, gene expression of both ANP and BNP is 
reportedly upregulated in animal models of MI and heart failure (10, 16, 20, 23) and in 
human heart disease (12, 21). Whereas ANP is expressed primarily in the atria in adults, the 
ventricle is the major site of both ANP and BNP expression in embryos (3). The appearance 
of increased ANP expression in adult ventricles is a marker for the induction of the 
embryonic gene program during the development of hypertrophy (6). It has been reported 
that ANP inhibits cardiac hypertrophy in cultured cardiac myocytes (1, 11, 24) and that ANP 
effects apoptosis in cardiac myocytes in culture (28). In addition to inhibiting cardiac 
hypertrophy, the three natriuretic peptides ANP, BNP, and C-type natriuretic peptide (CNP) 
suppress cardiac fibroblast growth (5). This raises the possibility that these peptides may 
function in a paracrine manner to modulate the development of cardiac hypertrophy and 
fibrosis during remodeling of the cardiac ventricle.
Mice lacking natriuretic peptide receptor NPR-A (Npr1–/–) have marked cardiac 
hypertrophy and fibrosis disproportionate to their increased blood pressure (13, 19). The 
cardiac hypertrophy observed in these Npr1–/– mice is greater than that seen in other mouse 
models of hypertension, suggesting the NPR-A pathway directly modulates the hypertrophic 
response independent of blood pressure. Additional support for this hypothesis was provided 
by a recent study in which the blood pressure of Npr1–/– mice was maintained within the 
normal range by chronic treatment with antihypertensive agents without resulting in 
significantly diminished cardiac hypertrophy. Furthermore, Npr1–/– mice had a greater 
hypertrophic response than control mice to pressure overload induced by transverse aortic 
constriction (13). Therefore, it appears that the NPR-A pathway directly regulates cardiac 
hypertrophy. Furthermore, we hypothesize that local factors involved in the hypertrophic 
response may regulate expression of the natriuretic peptides within cardiac tissue.
To further characterize the effects of the deletion of the NPR-A gene on expression of the 
natriuretic peptide system and the hypertrophic response it elicits, ANP and BNP gene 
expression in adult hearts and embryonic tissues of Npr1–/– mice were examined using the 
technique of in situ hybridization and compared with those of wild-type (WT) control mice. 
The expression of ANP and BNP in the ventricles of adult Npr1–/– mice was quantified by 
real-time polymerase chain reaction (PCR) by using the Taqman assay system. The 
distribution of ANP immunoreactivity (IR) in adult Npr1–/– and WT hearts was compared 
with the sites of cardiac fibrosis. Associated levels of circulating ANP in Npr1–/– and WT 
mice was determined by radioimmunoassay.
MATERIALS AND METHODS
Generation of Npr1–/– mice
Mouse experiments were carried out under protocols approved by the Institutional Animal 
Care and Use Committees of the University of North Carolina. Most of the studies, unless 
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otherwise stated, were performed on Npr1–/– and WT control mice backcrossed at least six 
generations to C57BL/6 mice derived from the original mutants, as previously reported (19).
Adult male and female Npr1–/– and WT mice (n = 4 per group) ranging from 4 to 12 mo of 
age were euthanized with an anesthetic overdose, and the hearts were rapidly dissected and 
then immersion fixed in 4% paraformaldehyde in 0.1 M borate buffer (pH 9.5). Embryos 
from mice of a mixed 129/C57BL6 genetic background were obtained from timed pregnant 
mice euthanized at 12 and 16 days post coitum. The embryos were dissected out of the 
uterine horns and separated from the placenta and were immersion fixed as above. Tissues 
were stored at 4°C. One day before being sectioned, tissues were transferred to a 
paraformaldehyde solution containing 10% sucrose, which was used as a cryoprotectant, and 
then embedded in OTC medium (Miles; Elkhart, IN).
Generation of ANP and BNP probe sequences
Riboprobes for in situ hybridization were generated by in vitro transcription from ANP and 
BNP DNA templates that had been extended by the PCR so that the 5′ ends of each strand 
encoded the T3 or T7 RNA polymerase promoter sequences, as described below. 
Oligonucleotide primers were designed from the published murine ANP (22) and BNP (18) 
DNA sequences, and encompassed exon 2 of each of these genes coding regions. A DNA 
fragment of 350 bp was generated by PCR of mouse genomic DNA using primers for ANP 
(ANP forward primer, 5′-GAACCTGCTAGACCACCT; reverse primer, 5′-
CCTAGTCCACTCTGGGCT). A 240-bp mouse BNP product was PCR amplified using 
specific BNP primers (BNP forward primer, 5′-AAGCTGCTGGAGCTGATAAGA; reverse 
primer, 5′-GTTACAGCCCAAACGACTGAC). PCR amplicon sequences were confirmed 
by sequencing.
Riboprobe synthesis by in vitro transcription using T3 and T7 RNA polymerase was 
performed on PCR-generated templates, as described by Logel et al. (15). A second round of 
PCR amplification was performed on the ANP and BNP PCR templates generated above 
with primers with 5′ extensions encoding the T3 and T7 RNA polymerase promoter 
sequences on the sense and antisense strands, respectively, as illustrated by the following 
ANP primer set. The RNA polymerase promoter sequence is underlined and the ANP-
specific sequence is in bold: ANP forward (T3) primer, 5′-
CAGAGATGCAATTAACCCTCACTAAAGGGAGA-GAACCTGCTAGACCACCT and 
ANP reverse (T7) primer, 5′-CCAAGCTTCTAATACGACTCACTATAGGGA-
CCTAGTCCACTCTGGGCT.
Generation of T3/T7 extensions to the murine ANP and BNP DNA fragments was 
performed by PCR using parameters identical to those described by Logel et al. (15). After 
amplification of each natriuretic peptide, a single PCR product that was ~70 bp larger than 
the original fragment was visualized on a 0.75% agarose gel. ANP and BNP riboprobes 
were generated by the procedure of in vitro transcription incorporating [35S]CTP, as 
previously described (3, 4).
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The method of in situ hybridization was used to study ANP and BNP gene expression in 
cardiac and embryonic tissues from Npr1–/– and WT animals. The hybridization protocol 
was performed on 20-μm-thick cryostat sections by following the methods of Simmons et al. 
(25). Briefly, the slides were washed twice in 0.05 M KPO4-buffered saline to remove the 
embedding compound and postfixed in 10% neutral buffered formalin. Prehybridization 
treatment included 0.25% acetic anhydride in 0.1 M triethanolamine to block positive 
charges on the tissue, dehydration through increasing ethanol concentrations, and vacuum 
drying the tissue. Hybridization was performed at 55°C overnight with 1 × 107/ml probe in 
100 μl of hybridization solution (25). A probe was applied to each slide, coverslipped, and 
sealed with DPX mountant (BDH; Poole, UK). After the coverslip was removed, the slides 
were rinsed four times in standard saline citrate (SSC) and incubated in RNAse A (20 μg/ml) 
at 37°C for 30 min. Sections were washed in decreasing concentrations of SSC, finishing 
with a high-stringency wash of 0.1× SSC at 68°C, dehydrated through ascending 
concentrations of ethanol, and vacuum dried. The slides were exposed to autoradiographic 
film (Hyperfilm-MP, Amersham; Little Chalfont, UK) for 1–2 days and then dipped in 
NTB-2 nuclear track emulsion (Eastman Kodak; Rochester, NY). Slides were exposed for 
14 days and then developed and counterstained with hematoxylin and eosin. Adjacent 
sections were hybridized with ANP and BNP and their respective sense probes.
Measurement of ANP and BNP expression using Taqman assay
At death, hearts from adult male and female Npr1–/– and WT mice (n = 7 per group) were 
snap-frozen in liquid nitrogen and stored at –80°C in RNAlater solution (Ambion; Austin, 
TX) until RNA extraction. RNA samples were prepared from homogenized tissue with the 
use of an automated machine (model 7700, ABI; Foster City, CA). mRNA expression of 
ANP and BNP were characterized by real-time quantitative reverse transcription-PCR with a 
ABI 6700 machine. Primers for ANP were 5′-GAGAAGATGCCGGTAGAAGA-3′ and 5′-
AAGCACTGCCGTCTCTCAGA-3′ (forward and reverse, respectively), and the probe for 
ANP detection was 5′-FAM-ATGCCCCCGCAGGCCCGG-Tamra-3′. Primers for BNP 
were 5′-CTGCTGGAGCTGATAAGAGA-3′ and 5′-TGCCCAAAGCAGCTTGAGAT-3′, 
and the probe for BNP detection was 5′-FAM-CTCAAGGCAGCACCCTCCGGG -
Tamra-3′. All reactions included a β-actin internal standard. The primers used for β-actin 
amplification were 5′-CTGCCTGACGGCCAAGTC-3′ and 5′-
CAAGAAGGAAGGCTGGAAAAGA-3′. The probe for β-actin detection was 5′-TET-
CACTATTGGCAACGAGCGGTTCCG-Tamra-3′. The reactions were performed with 0.5 
μg total RNA with minor differences from ABI 6700 manufacturer's instructions.
ANP plasma levels in Npr1–/– and WT mice
Whole blood samples from Npr1–/– and WT mice (n = 8 each for WT males and females, n 
= 5 Npr1–/– males, and n = 6 Npr1–/– females) were collected in EDTA tubes. Plasma was 
separated by centrifugation and stored at –80°C before analysis. Plasma (200 μl) was 
extracted through Sep-Pak C18 columns (Waters; Milford, MA) and used for ANP 
radioimmunoassay. ANP radioimmunoassay was performed by the method described by 
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Yandle et al. (29). Cross reactivity in this ANP assay with mouse ANP-28 was 100%, and 
with mouse BNP-45 it was <0.02%.
ANP immunohistochemistry and histology
Immunohistochemistry for the detection of ANP-IR (ANP–) was performed on 7-μm-thick 
sections of paraffin-embedded hearts from Npr1–/– and WT mice with the use of a 
peroxidase-labeled streptavidin-biotin kit (DAKO; Carpinteria, CA). The antiserum against 
rat ANP (29) was used at a final dilution of 1:500. Adjacent heart sections were also stained 
with Masson trichrome for the presence of collagen, thus indicating cardiac fibrosis.
Statistical analyses
Two-way analysis of variance was used to analyze the genotype and gender effects on the 
heart weight-to-body weight ratio (HW/BW), left ventricular (LV) ANP, and BNP mRNA 
and circulating ANP plasma levels. Associations between age, HW/BW, LV ANP, and BNP 
mRNA were tested for significance using Pearson's correlation coefficients.
RESULTS
Npr1–/– mice are hypertensive and have cardiac hypertrophy versus Npr1 mice at baseline
A representative sample of Npr1–/– mice had significantly higher blood pressure levels than 
WT control mice (Npr1–/– = 126 ± 3 mmHg, n = 8 vs. WT = 108 ± 2 mmHg, n = 26). 
However, there was no significant difference in the blood pressures between male and 
female Npr1–/– mice, which is consistent with previous reports (13). Hearts of the Npr1–/– 
mice were also significantly larger than those of WT mice as presented as HW/BW in Table 
1.
In situ hybridization reveals that Npr1–/– mice have increased ventricular expression of 
ANP and BNP
Expression of ANP in the whole hearts of Npr1–/– and WT mice are shown in Fig. 1. In the 
atria, ANP expression was very intense in both Npr1–/– and WT mice. However, in the 
ventricles, ANP expression was markedly increased in Npr1–/– mice compared with WT 
controls. This was particularly pronounced in female hearts, with intense expression along 
the endocardium lining the left ventricle (LV) and in patches within the walls of both the LV 
and right ventricles. Increased thickness of the LV free wall was observed in both male and 
female Npr1–/– mice compared with the LV of WT mice. Expression of BNP in the whole 
hearts of Npr1–/– and WT mice are shown in Fig. 2. Similar to ANP, BNP expression was 
greatly increased in the LV of Npr1–/– mice compared with WT controls. This was most 
marked in female Npr1–/– mice.
Expression quantitated by Taqman system
To quantify the ventricular ANP and BNP expression in Npr1–/– and WT mice, RNA was 
extracted from LV tissue from the hearts, and levels of ANP and BNP mRNA were assessed 
using Taqman real-time PCR (Table 1). These data confirmed the results of the in situ 
hybridization, with LV ANP mRNA being significantly greater in Npr1–/– mice than in WT 
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mice. There was a highly significant effect of both genotype (P < 0.001) and gender (P < 
0.001) on ANP mRNA. The increase in ANP mRNA was 3.3 times greater in female 
Npr1–/– mice compared with WT mice, whereas the increase in ANP mRNA was 1.4 times 
greater in male Npr1–/– mice compared with WT mice. The difference between the genders 
was also significant (P < 0.001). LV BNP mRNA was increased by 60% in female Npr1–/– 
mice compared with female WT mice. However, neither the effect of genotype nor gender 
was statistically significant for BNP expression.
There was a highly significant correlation between HW/BW and both LV ANP mRNA (r = 
0.699, P < 0.001) and LV BNP mRNA (r = 0.374, P < 0.05). There was also a highly 
significant correlation between LV ANP and LV BNP mRNA (P < 0.001). There was no 
significant effect of age (from 4 to 16 mo) on HW/BW ratio, ANP or BNP mRNA, or ANP 
or BNP circulating levels in either males or females (13).
Circulating ANP levels are elevated in Npr1–/– mice
Circulating concentrations of ANP were also measured in the plasma of Npr1–/– mice and 
WT mice (Table 1). Plasma ANP was significantly higher in male Npr1–/– than WT mice (P 
= 0.005). Surprisingly, however, in female mice, there was no significant difference between 
Npr1–/– and WT control mice for plasma ANP. Male Npr1–/– mice had significantly greater 
levels of plasma ANP than female Npr1–/– mice (P = 0.03), whereas in WT mice, male and 
female plasma ANP concentrations were not significantly different.
ANP expression and IR are localized to areas of fibrosis
The presence of ANP-IR in female (Fig. 3) and male Npr1–/– and WT hearts was visualized 
using immunohistochemistry. In Npr1–/– hearts, intense ANP-IR was observed in the inner 
free LV wall (Fig. 3A), consistent with regions of ANP gene expression, as described 
previously (Fig. 1).
In addition, a high-power examination of LV sections indicated diffuse patches of intense 
ANP-IR in Npr1–/– mice, and these were associated with regions of fibrosis, particularly in 
the LV free wall. This was confirmed by staining adjacent tissue blocks with Masson 
trichrome stain, which stains the collagen in fibrotic tissue blue. Regions of interstitial 
fibrosis were colocalized with ANP-IR (indicated by arrows in Fig. 3A). Examples of 
regions of intense ANP-IR colocalized with areas of perivascular fibrosis in the LV are 
shown in Fig. 3A, right. Colocalization of interstitial fibrosis with areas of ANP and BNP 
gene expression is shown in Fig. 3B. Fibrosis was more evident in the LV of female Npr1–/– 
mice than male Npr1–/– mice, paralleling the greater HW/BW and ANP and BNP mRNA 
levels quantified by the Taqman assay in female hearts, as described earlier.
ANP and BNP expression in embryos
Expression of ANP and BNP was also examined in developing mouse embryos. At 11 days 
of gestation, strong expression of ANP (Fig. 4) and BNP (Fig. 5) could be seen in the 
developing heart, but was similar in Npr1–/– mice and control embryos. However, at 16 days 
gestation, Npr1–/– embryos showed increased cardiac expression of ANP and BNP 
compared with control embryos. Furthermore, from 16 days of gestation, ANP and BNP 
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expression was also increased at extracardiac sites, including the lung, skeletal muscle, 
bladder, and vertebrae.
DISCUSSION
This study demonstrates that disruption of the receptor signaling pathway for the cardiac 
natriuretic peptides ANP and BNP results in augmented gene and protein expression of 
those peptides in the cardiac ventricles. This increased expression is highly correlated with 
the degree of cardiac hypertrophy. In addition, patches of ANP and BNP expression and IR 
were colocalized with regions of both interstitial and perivascular fibrosis in the ventricles. 
In contrast, the ANP and BNP expression seems to be less closely related to the level of 
blood pressure or the concentrations of these peptides in the circulation. These findings 
suggest that local factors associated with cardiac hypertrophy and fibrosis may be a major 
drive to the activation of ANP and BNP expression in adult cardiac ventricles.
Knowles et al. (13) showed that Npr1–/– mice have cardiac hypertrophy disproportionate to 
their increased blood pressure. Furthermore, when the blood pressure of these mice was 
maintained at control levels by chronic treatment with hypertensive drugs, the hypertrophy 
of Npr1–/– mice was not diminished. These results suggest that the NPR-A receptor system 
participates in regulating cardiac hypertrophy independent of blood pressure.
During hypertrophy, several biochemical and mechanical factors trigger a series of 
responses in myocardial cells in vitro, culminating in an increase in cell size and sarcomeric 
organization (26). These responses occur in a specific temporal sequence, with the triggering 
of the early gene cascade (i.e., c-jun, c-fos, c-myc, and egr-1) preceding activation of the 
embryonic repertoire, including ANP, α-skeletal actin, and β-myosin heavy chain. The ANP 
gene, as a representative of the embryonic repertoire, has been of particular interest in that 
reactivation of its expression in adult ventricular myocardium has become one of the most 
sensitive markers of hypertrophy (6). Furthermore, recent studies suggest that the natriuretic 
peptides may have a direct effect in regulating cardiac hypertrophy, because it has been 
reported that ANP inhibits cardiac hypertrophy in cultured cardiac myocytes (1, 11, 24) and 
that ANP induces apoptosis in cardiac myocytes in culture (28). This is supported by other 
mouse models of cardiac hypertrophy. For example, in transgenic mice with cardiac 
overexpression of a mutant α-myosin heavy chain gene (27), ANP mRNA in the LV 
increased approximately threefold and was found in regions of tissue pathology.
In addition to inhibiting cardiac hypertrophy, it has been proposed that all three natriuretic 
peptides, ANP, BNP, and CNP, suppress cardiac fibroblast growth (5). This raises the 
possibility that these peptides may function in a paracrine manner to modulate the 
development of cardiac fibrosis during cardiac hypertrophy. We (2) have shown that ANP is 
transiently expressed by fibroblasts during the formation of the fibrotic scar after myocardial 
infarction. In that study, treatment of cultured cardiac fibroblasts with transforming growth 
factor-β induced the expression of α-smooth muscle actin, characteristic of the 
transformation to myofibroblasts, and raised ANP concentrations in the medium. We have 
now demonstrated strong ANP and BNP mRNA and ANP protein expression in fibrotic 
tissue in two different animal models of cardiac fibrosis. It appears that, although ANP and 
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BNP gene expression may be repressed in fibroblasts in normal physiology, transcription is 
activated in pathological states. In our previous study (2) of ovine myocardial infarction, 
ANP was colocalized to myofibroblasts. Thus we propose that ANP may be secreted on the 
phenotypic switch of fibroblasts to myofibroblasts, the cell type responsible for collagen 
deposition in the process of scar formation. We hypothesize that the release of ANP may 
inhibit the proliferation of fibroblasts and the deposition of collagen.
The regions of intense ANP and BNP expression observed along the endocardium of the LV 
free wall is likely to result from multiple stimuli. These include hypertrophy, hemodynamic 
overload, and regional mechanical stresses in response to elevated blood pressure in Npr1–/– 
mice compared with WT mice. However, a greater increase in ANP and BNP gene 
expression and ANP-IR was seen in the female Npr1–/– mice compared with male Npr1–/– 
mice, despite there being no significant difference in blood pressures of male versus female 
Npr1–/– mice. Gender-specific differences in ANP and BNP expression have been observed 
during the development of hypertension in humans and animals (7), and in that paper, it was 
suggested that estrogen may increase cardiac natriuretic peptide expression via activation of 
the renin-angiotensin system. Because tissue renin-angiotensin is implicated in both cardiac 
hypertrophy and fibrosis (7), this may provide a possible explanation for the marked 
increase in ANP and BNP gene expression and IR seen in female compared with male 
Npr1–/– mice.
Increased cardiac expression of ANP and BNP is initiated before birth in Npr1–/– mice, as 
demonstrated by in situ hybridization in embryos. Knowles et al. (13) reported that the 
hearts of Npr1–/– mice are enlarged at birth. Our examination of sections of 16-day-old 
embryos suggests that the hearts of Npr1–/– mice are larger than control mice aged as early 
as 16 days of gestation. These developing embryos are unlikely to have been exposed to 
high blood pressure in utero because the blood pressure in the fetus is governed by the 
maternal-fetal circulatory system via the placenta. This suggests that the increased ANP and 
BNP expression in the developing hearts of Npr1–/– mice may be activated by the 
hypertrophy. Thus a feedback loop may have started during development, with the 
deficiency of NPR-A pathways that would normally regulate the growth of cardiac 
myocytes leading to hypertrophy, and a consequent compensatory rise of ANP and BNP 
expression in the developing heart.
The ventricular expression of the natriuretic peptides was more closely related to heart 
weight than either blood pressure or circulating levels of ANP in this study, particularly with 
regard to the differences between male and female mice. Whereas blood pressure and its 
mechanical effect on the heart wall is one of the primary triggers for natriuretic peptide 
expression in normal physiology (8), local tissue factors may regulate the activation of the 
ventricular expression during the development of hypertrophy. The lack of correlation 
between ventricular levels of ANP and BNP mRNA and circulating peptide concentrations 
suggest that ANP and BNP secretion from the atria, which was not measured in this study, 
was making a greater contribution to plasma levels that the ventricular secretion.
In summary, this study provides evidence that hypertrophy itself may be activating ANP and 
BNP expression in the ventricles, independent of blood pressure and starting during 
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development. Furthermore, areas of intense ANP and BNP expression in the ventricle were 
associated with regions of fibrosis, suggesting an intimate role between the fibrotic process 
and local natriuretic peptide production. Overall, this study suggests that within the 
ventricles, the cardiac peptides ANP and BNP participate in the complex interplay of local 
tissue factors involved in the process of myocyte hypertrophy and cardiac fibrosis, which 
appears to be independent of blood pressure and their secretion into the circulation.
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Representative autoradiographs of longitudinal sections through entire mouse hearts from 
wild-type (WT) male (A) and female (B) mice and natiuretic peptide receptor-A knockout 
(Npr1–/–) male (C) and female (D) mice hybridized with atrial natriuretic peptide (ANP) and 
ANP control probe (E). Positive ANP expression is observed as darkened regions in the left 
atria (la), left ventricle (lv), right atria (ra), and right ventricle (rv).
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Representative autoradiographs of longitudinal sections through entire male and female WT 
(A and B) and male and female Npr1–/– (C and D) adult mouse hearts hybridized with brain 
natriuretic peptide (BNP) and BNP control probe (E). Positive BNP expression is observed 
as darkened regions (see Fig. 1 for abbreviations).
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A: Masson trichrome staining (top) and ANP immunohistochemistry (bottom) of female 
Npr1–/– and WT hearts. Blue color with Masson trichrome staining indicates collagen 
deposition, which is characteristic of fibrosis. Brown staining indicates ANP 
immunoreactivity (IR) and can be seen colocalized with perivascular fibrosis. Contents of 
the blood vessels also stain brown due to IR of blood clots within the lumen. White arrows 
show regions of left ventricular fibrosis and the colocalization of ANP-IR to these regions. 
Black arrows show ANP-IR at nonfibrotic regions of the inner free wall of the left ventricle. 
ELLMERS et al. Page 13






















Scale bars in left and middle represent 500 μM, and bars in right represent 50 μM. B: 
Masson trichrome staining (top) and dark-field photomicrographs of representative 
longitudinal sections through the left ventricles of female Npr1–/– and WT hearts hybridized 
with ANP and BNP. Blue color with Masson trichrome staining indicates collagen 
deposition, which is characteristic of fibrosis. Positive ANP and BNP gene expression is 
seen as bright silver grains above expressing cells. White arrows illustrate regions of ANP 
and BNP expression colocalized to areas of left ventricular fibrosis. Scale bars represent 200 
μM. a, Atria.
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Representative autoradiographs of longitudinal sections through 11-day-old (11d) and 16-
day-old (16d) Npr1–/– embryos (A and C) and WT embryos (B and D) hybridized with ANP 
and ANP control probe (E). Positive ANP expression is observed as darkened regions in the 
atrium (a), ventricle (v), lung (l), skeletal muscle (sm), bladder (b), and vertebrae (vt).
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Representative autoradiographs of longitudinal sections through 11- and 16-day-old Npr1–/– 
embryos (A and C) and WT embryos (B and D) hybridized with BNP and BNP control 
probe (E). Positive BNP expression is observed as darkened regions (see Fig. 4 for 
abbreviations).
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Table 1
HW/BW ratios, levels of ANP and BNP mRNA in LV, and plasma concentrations of ANP in male and female 
backcrossed Npr1–/– mice compared with WT control mice
HW/BW LV ANP mRNA, ng/mg LV BNP mRNA, ng/mg Plasma ANP, pmol/l
Male Npr1–/– 6.7 ± 0.2* 159 ± 16 54 ± 6 22.5 ± 3.9*
Male WT 5.4 ± 0.2 111 ± 14 69 ± 11 11.6 ± 0.5
Female Npr1–/– 7.0 ± 0.2* 414 ± 57* 146 ± 38 13.2 ± 1.3
Female WT 5.1 ± 0.2 124 ± 25 90 ± 22 15.6 ± 1.6
Values are means ± SE. ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; Npr1–/–, mice lacking the gene that encodes natriuretic 
peptide receptor-A; WT, wild type; HW/BW, heart weight-to-body weight ratio; LV, left ventricular. HW/BW is expressed as a ratio ×10–3. LV 
ANP mRNA refers to the expression of ANP and BNP mRNA quantified by Taqman assay.
*
P < 0.001, statistically significant difference between Npr1–/– and WT control.
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